

PHARMACOPOEIAL DISCUSSION GROUP

SIGN-OFF DOCUMENT, Rev. 1

NAME: DISSOLUTION

The terminology used to describe modified-release dosage form has not been harmonized. The following terminology equivalency table is given to aid understanding of the sign-off text.

USP	EP	JP
Immediate-Release DF	Immediate-Release DF	Not Described
Modified-Release DF	Modified-Release DF	Not Described
-Extended-Release DF	Prolonged-Release DF	Not Described
-Delayed-Release DF	Gastro-Resistant DF	Enteric-Coated Preparations

Residual Differences:

- 1) In the USP, where dissolution failure occurs for dosage forms employing gelatin, the test may be repeated with the addition of enzymes.
- 2) USP specifies the use of USP calibrators for the calibration of dissolution apparatus.
- 3) EP and JP will allow both pulsated and non-pulsated flow for Apparatus 4.
- 4) As indicated in the text, JP will not include Apparatus 3, nor sections related to delayed-release dosage forms.
- 5) Procedure, Apparatus 1 or 2, EP will allow performance of the test without removal of the thermometer if validation has been carried out in this way.
- 6) The USP will specify the procedure and acceptance criteria for pooled dissolution.

<u>AMJ</u> Agnès ARTIGES	<u>8 November 2005</u>
European Pharmacopoeia	Date
<u>Hiromichi Ogasawara</u> for AKIRA KAWAHARA	<u>8 November 2005</u>
Japanese Pharmacopoeia	Date
<u>Eric B Sheinon</u> Eric B Sheinon	<u>8 November 2005</u>
United States Pharmacopoeia	Date